Nastilox (Clopidogrel)

Clopidogrel acts on platelet aggregation pathways to lower the incidence of cardiovascular complications.

• Prevention of atherothrombotic events in patients with a history of myocardial infarction, stroke, or established peripheral arterial disease: reduces risk of recurrent heart attack, stroke and vascular death.
• Secondary prevention after acute coronary syndrome: lowers the likelihood of subsequent myocardial infarction and cardiovascular mortality.
• Prevention of stent thrombosis following percutaneous coronary intervention: helps maintain vessel patency after stent placement.

• Clopidogrel is an irreversible antagonist of the platelet P2Y12 ADP receptor. By blocking ADP binding, it prevents the activation of the glycoprotein IIb/IIIa complex, thereby inhibiting fibrinogen cross‑linking and platelet aggregation, which reduces thrombus formation in arterial circulation.

Clopidogrel may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia.
• Minor bleeding: easy bruising, gum bleeding or occasional nosebleeds.
• Headache: mild to moderate intensity.
• Diarrhea: loose stools without severe dehydration.

Serious or Rare Side Effects

• Severe bleeding: gastrointestinal hemorrhage, intracranial bleeding or hematuria.
• Thrombotic thrombocytopenic purpura (TTP): a rare blood disorder with low platelet count.
• Allergic reactions: rash, itching, swelling or anaphylaxis.
• Hepatotoxicity: elevated liver enzymes indicating liver injury.

Before initiating therapy, clinicians should assess individual bleeding risk and review concomitant medications.

• Assess bleeding risk: evaluate history of ulcers, hemorrhagic disorders or recent surgery.
• Monitor platelet function: periodic laboratory testing may be warranted in high‑risk patients.
• Renal or hepatic impairment: dose adjustment may be required based on clinical judgment.
• Pregnancy and lactation: use only if potential benefit outweighs potential risk to fetus or infant.
• Discontinue before surgery: stop clopidogrel as advised by the operating physician to reduce intra‑operative bleeding.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Clopidogrel interacts with several drug classes that can alter its antiplatelet effect or increase bleeding risk.

Major Interactions (Avoid)

• Strong CYP2C19 inhibitors (e.g., fluconazole, voriconazole, omeprazole): may reduce conversion to the active metabolite and diminish efficacy.
• Concurrent use of anticoagulants (e.g., warfarin, heparin) or other antiplatelet agents (e.g., aspirin, ticagrelor): markedly increases bleeding risk.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): additive effect on gastrointestinal bleeding.

Moderate Interactions (Monitor Closely)

• Selective serotonin reuptake inhibitors (SSRIs) or serotonin‑norepinephrine reuptake inhibitors (SNRIs): may enhance bleeding tendency.
• Proton pump inhibitors (excluding pantoprazole): potential reduction in antiplatelet activity.
• Statins metabolized by CYP3A4 (e.g., atorvastatin): may increase plasma concentrations of clopidogrel's active metabolite.